Activation of circulating platelets in vaccine‐induced thrombotic thrombocytopenia and its reversal by intravenous immunoglobulin
Open Access
- 16 August 2021
- journal article
- letter
- Published by Wiley in British Journal of Haematology
- Vol. 196 (1) , 234-237
Abstract
No abstract availableKeywords
Funding Information
- National Health and Medical Research Council
This publication has 16 references indexed in Scilit:
- US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021JAMA, 2021
- SARS-CoV-2 Vaccine–Induced Immune Thrombotic ThrombocytopeniaNew England Journal of Medicine, 2021
- Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 VaccinationNew England Journal of Medicine, 2021
- A flow cytometric assay to detect platelet-activating antibodies in VITT after ChAdOx1 nCov-19 vaccinationBlood, 2021
- The Emerging Threat of (Micro)Thrombosis in COVID-19 and Its Therapeutic ImplicationsCirculation Research, 2020
- Intravenous Immune Globulin to Prevent Heparin-Induced ThrombocytopeniaNew England Journal of Medicine, 2018
- Monocyte-bound PF4 in the pathogenesis of heparin-induced thrombocytopeniaBlood, 2010
- Heparin-induced thrombocytopenia: new evidence for the dynamic binding of purified anti-PF4-heparin antibodies to platelets and the resultant platelet activation.2000
- Heparin-induced thrombocytopenia: new evidence for the dynamic binding of purified anti-PF4–heparin antibodies to platelets and the resultant platelet activationBlood, 2000
- Platelet activation as a potential mechanism of GP IIb/IIIa inhibitor-induced thrombocytopeniaThe American Journal of Cardiology, 1999